Novavax, Inc. (NASDAQ: NVAX) shares are trading higher after the company, along with Serum Institute of India, announced the Philippine FDA has granted emergency use authorization for Novavax’s COVID-19 vaccine.
“Today’s announcement from EMA brings Novavax another step closer to our goal of ensuring broad global access to our protein-based COVID-19 vaccine across Europe,” said Stanley C. Erck, President and Chief Executive Officer, Novavax.
“Novavax looks forward to providing an additional vaccine option in Europe, built on a proven, well-understood technology platform, and thanks the European Commission for its ongoing partnership and confidence in our COVID-19 program,” Erck stated.
Novavax has a 52-week high of $331.68 and a 52-week low of $85.62.
See more from Benzinga
© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
